Literature DB >> 3171480

Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice.

I Gresser1, C Maury, F Vignaux, O Haller, F Belardelli, M G Tovey.   

Abstract

Friend erythroleukemia cells (FLC) (H-2d) injected intravenously into adult syngeneic DBA/2 or allogeneic C57B1/6 (H-2b) or C3H (H-2k) mice lodge in the liver but only multiply in the liver of syngeneic mice. Our results indicated that endogenous IFN-alpha/beta was a crucial factor in preventing the multiplication of FLC in the liver of adult allogeneic mice. (a) Treatment of allogeneic adult C57B1/6 or C3H mice with polyclonal antibody to mouse IFN-alpha/beta (but not antibody to IFN-gamma) completely abrogated the resistance to the multiplication of FLC in the liver and 87% of tumor-injected, antibody-treated C57B1/6 mice died with extensive tumor involvement of the liver. In contrast, after intravenous inoculation FLC do not multiply at all (or very rarely) in the liver of adult C57B1/6 mice left untreated or treated with a variety of control globulins, and no deaths occurred. (b) 8 h after intravenous inoculation of FLC, poly(A)+ RNA hybridizable with specific DNA probes for mouse IFN-alpha or -beta (but not -gamma) was present in the liver of injected C57B1/6 mice. Using the expression of the Mx protein as an indicator of the presence of IFN-alpha/beta, we showed that Mx+ congenic C57B1/6 mice injected with FLC exhibited a marked increase in the expression of the Mx protein in the liver, spleen, kidney and lung, and this increase was blocked by treatment of mice with antibody to IFN-alpha/beta. The possibility that different host mechanisms are elicited depending on the site of tumor growth in allogeneic mice is discussed. IFN-alpha/beta appears to be of particular importance in determining the resistance of the liver to FLC in allogeneic mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3171480      PMCID: PMC2189088          DOI: 10.1084/jem.168.4.1271

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain.

Authors:  E Affabris; C Jemma; G B Rossi
Journal:  Virology       Date:  1982-07-30       Impact factor: 3.616

Review 2.  Inborn resistance of ice to orthomyxoviruses.

Authors:  O Haller
Journal:  Curr Top Microbiol Immunol       Date:  1981       Impact factor: 4.291

3.  Structure and expression of a cloned cDNA for mouse interferon-beta.

Authors:  Y Higashi; Y Sokawa; Y Watanabe; Y Kawade; S Ohno; C Takaoka; T Taniguchi
Journal:  J Biol Chem       Date:  1983-08-10       Impact factor: 5.157

4.  Interferon induction in human mixed leukocyte-tumor-cell reactions: evidence for restriction to a certain lineage expressing glycophorin A.

Authors:  R Berger; W Knapp; H Kirchner
Journal:  Int J Cancer       Date:  1984-07-15       Impact factor: 7.396

5.  Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus.

Authors:  F Belardelli; F Vignaux; E Proietti; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

6.  Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.

Authors:  F Belardelli; I Gresser; C Maury; M T Maunoury
Journal:  Int J Cancer       Date:  1982-12-15       Impact factor: 7.396

7.  Structure and expression of cloned murine IFN-alpha genes.

Authors:  G D Shaw; W Boll; H Taira; N Mantei; P Lengyel; C Weissmann
Journal:  Nucleic Acids Res       Date:  1983-02-11       Impact factor: 16.971

8.  Cloning and expression of murine immune interferon cDNA.

Authors:  P W Gray; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

9.  Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities.

Authors:  G L Spitalny; E A Havell
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

10.  Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors.

Authors:  I Gresser; F Belardelli; C Maury; M T Maunoury; M G Tovey
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Expression of the genes of interferons and other cytokines in normal and diseased tissues of man.

Authors:  M G Tovey
Journal:  Experientia       Date:  1989-06-15

Review 2.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

3.  Influence of the site of tumor growth on the capacity of a low tumorigenic line of Friend erythroleukemia cells to differentiate.

Authors:  I Gresser; J Moss; D Woodrow; C Le Bousse; C Maury; E Proietti; F Belardelli
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

4.  Interferon-regulated Mx genes are not responsive to interleukin-1, tumor necrosis factor, and other cytokines.

Authors:  A Simon; J Fäh; O Haller; P Staeheli
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

5.  Human immunodeficiency virus (HIV)-infected tumor xenografts as an in vivo model for antiviral therapy: role of alpha/beta interferon in restriction of tumor growth in nude mice injected with HIV-infected U937 tumor cells.

Authors:  P Puddu; C Locardi; P Sestili; F Varano; C Petrini; A Modesti; L Masuelli; I Gresser; F Belardelli
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

6.  Endogenous interferon alpha/beta produced by Kupffer cells inhibits interleukin-1, tumor necrosis factor alpha production and interleukin-2-induced activation of nonparenchymal liver cells.

Authors:  S P Tzung; S A Cohen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Dendritic cells prime natural killer cells by trans-presenting interleukin 15.

Authors:  Mathias Lucas; William Schachterle; Karin Oberle; Peter Aichele; Andreas Diefenbach
Journal:  Immunity       Date:  2007-03-29       Impact factor: 31.745

Review 8.  Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.

Authors:  Glauco Akelinghton Freire Vitiello; Wallax Augusto Silva Ferreira; Vladmir Cláudio Cordeiro de Lima; Tiago da Silva Medina
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.